ArticleDiabetes, obesity & metabolism2025
Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study.
Helen Tesfaye et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.